Numinus Wellness (TSE:NUMI) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Numinus Wellness Inc. has been greenlit by Health Canada to conduct a groundbreaking study on MDMA-assisted psychotherapy within a group setting, focusing on the therapy’s delivery and the optimal number of therapists required. The clinical trial also offers a unique training opportunity for practitioners to gain firsthand experience and insights into the therapeutic use of MDMA. This research contributes to the evolving understanding and potential integration of psychedelic-assisted treatments in mainstream mental health care.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.
